Blog
Practical guidance on manuscript preparation, peer review strategy, and getting published in top journals.
Upload your manuscript for a free readiness scan.
Product Comparisons · 11 min read
There are now several services that help researchers improve manuscripts before journal submission. They differ significantly in what they actually review, who does the reviewing, and what you get back. Here is the complete picture.
Nature Medicine rejects most manuscripts at the desk, before external peer review. The reasons are almost never about language. Here is what the journal's reviewers actually evaluate and how to prepare before submitting.
Top cardiology journals reject most submissions before external review. Circulation, JACC, and European Heart Journal have distinct reviewer expectations. Here is what pre-submission review looks like for manuscripts targeting this tier.
CNS journals - Nature Neuroscience, Neuron, Brain, and their equivalents - are among the hardest to crack in biomedical research. Here is what reviewers actually look for and how pre-submission review helps close the gap.
Nature rejects most submissions before a single external reviewer reads them. The reasons aren't about writing quality. Here's what the journal's editors actually look for and how to build a manuscript around those standards.
Science (IF 45.8) and Nature occupy the same prestige tier but have meaningfully different editorial priorities. Here's what Science reviewers look for and how to prepare a manuscript that gets past the desk.
Nature, Science, and Cell are often treated as a single prestige tier. They're not interchangeable. Here's how to decide which journal fits your manuscript and why targeting the wrong one wastes months.
Top oncology journals have among the highest desk rejection rates in medicine. Cancer Cell, JCO, and Cancer Discovery are looking for specific things that most manuscripts don't deliver. Here's what they want and how to close the gap before you submit.
Nature Immunology and Immunity are the top-tier venues for immunology research, with desk rejection rates above 60%. Here's what their reviewers look for and what pre-submission review covers for manuscripts targeting this tier.
Cell Metabolism and Nature Metabolism are the top venues for metabolic research. They have specific reviewer expectations that differ from other biology journals. Here's how to prepare a manuscript that passes their initial screening.
Infectious disease publishing spans clinical journals, microbiology journals, and translational hybrid venues. Each has specific reviewer expectations. Here's how to prepare a manuscript that's positioned correctly for the journal you're targeting.
Editage is a legitimate service with a large track record. Whether it's worth the investment depends entirely on what's actually holding your manuscript back. Here's the honest breakdown.
Pre-submission review isn't right for every manuscript or every researcher. Here's an honest breakdown of who benefits, what it costs in time and money, and when you're better off submitting without it.
The price range for pre-submission manuscript services is enormous - from free reciprocal peer review to $1,800 expert review. Here's exactly what each tier delivers and when it's worth the investment.
Manusights and ManuscriptsReviewer both offer pre-submission peer review, but they differ in reviewer credentials, pricing model, and what the review actually covers. Here's the direct comparison.
Reviewer3 is fast and affordable. Manusights is slower and costs more. If that were the whole comparison, Reviewer3 would win every time. Here's why the comparison is more nuanced - and which service is right for which manuscript.
Reviewer3 is a solid AI feedback tool. But if you're targeting a journal with IF above 10, or you've used AI feedback and still got rejected, you probably need something different. Here are the real alternatives.
AI peer review is fast, cheap, and getting better. Human expert review is slower, more expensive, and irreplaceable for specific situations. Here's the honest breakdown of when each one actually matters.
QED Science and Manusights both improve manuscripts before submission, but they do it in completely different ways. Here's the breakdown of what each service delivers and which one fits which manuscript.
AI peer review is genuinely useful. It's also genuinely limited in ways that matter for specific manuscripts. Here's the clear line between when AI feedback is sufficient and when you need a human scientist who's published at your target journal's tier.
Reviewer3 is a real AI peer review service used by thousands of researchers. Whether it's worth paying for depends on what your manuscript actually needs. Here's the honest breakdown.
Your first submission to a high-impact journal is a high-stakes moment. The reviewer standards at Nature, Cell, and their specialty equivalents aren't obvious from the outside. Here's what pre-submission review covers and when it genuinely helps PhD students.
If English isn't your first language, you're dealing with two distinct problems: language quality and scientific content. Most pre-submission services only address one of them. Here's what actually helps.
Postdoc publications aren't just papers - they're the evidence base for job applications, fellowships, and independent research grants. Here's how to use pre-submission review strategically for the manuscripts that matter most.
First submissions to high-impact journals fail for predictable reasons. The reviewer standards above IF 15 aren't intuitive and aren't taught anywhere. Here's what pre-submission review covers for researchers targeting this tier for the first time.
Drug development papers face strict reviewer expectations around translational claims, stats, and controls. Here's how pre-submission review helps biotech and pharma teams avoid slow rejection cycles.
Manusights and Enago solve different problems. If you're choosing between them, this side-by-side breakdown shows where each one fits.
Grant timelines and paper timelines are tightly linked. Here's how pre-submission review helps you protect submission dates, reviewer confidence, and funding momentum.
Some papers are tied to job searches, tenure packets, and promotion milestones. Here's when pre-submission review is worth it and how to use it well.
Paperpal and Manusights solve different problems. One improves writing clarity, the other pressure-tests the science before submission.
Trinka is useful for language quality. Manusights is for scientific quality control before submission.
Need the latest Nature Communications Impact Factor 2025 number? Use this evidence-based breakdown with JCR 2024 values and practical submission guidance.
Need the latest Scientific Reports Impact Factor 2025 number? Use this evidence-based breakdown with JCR 2024 values and practical submission guidance.
Need the latest PLOS ONE Impact Factor 2025 number? Use this evidence-based breakdown with JCR 2024 values and practical submission guidance.
Need the latest Science Advances Impact Factor 2025 number? Use this evidence-based breakdown with JCR 2024 values and practical submission guidance.
Submitting to IEEE Access? Learn what triggers desk rejections, how editors evaluate scope fit, and how to position papers to pass initial screening.
Compare Nature vs Science: JIF 48.5 vs 45.8, scope differences, acceptance rates, and which journal is the right fit for your research.
Compare Science vs Cell: JIF 45.8 vs 42.5, multidisciplinary vs cell biology focus, acceptance rates, and which journal is the right fit.
Compare Nature vs Science Advances: JIF 48.5 vs 12.5, editorial standards, acceptance rates, and determine which journal fits your research.
Compare Science Advances vs PNAS: JIF 12.5 vs 9.1, scope, acceptance rates, and determine which journal is the best fit for your paper.
JAMA and The Lancet are both top-tier general medical journals, but they reward different research.
BMJ and JAMA both flagship medical journals with different strengths.
Both top-tier, but Lancet is more selective.
Both top-tier Nature journals with different emphases.
Nature Medicine is clinical-translation focused, Cell is mechanistic.
The 2024 JCR Impact Factor for Construction and Building Materials is 8.0, placing it in Q1 of Materials Science & Construction/Building Technology. Here's what that means for your submission.
Physical Review D has an impact factor of 5.3 in the 2024 JCR. Here's where it sits in fundamental physics and what that metric does, and doesn't, tell you.
With a 30-35% overall acceptance rate and 35-40% desk rejection rate, Construction and Building Materials is highly selective. Here's what distinguishes papers that get accepted.
Expect 100-150 days from submission to first editorial decision at Construction and Building Materials, with publication typically 60-90 days after acceptance. Here's the realistic timeline.
Construction and Building Materials requires 7,000-10,000 word manuscripts with complete durability data, cost analysis, and construction relevance. Here's exactly what editors need.
Construction and Building Materials is a highly respected Q1 journal with strong impact and selectivity. But it's right for your paper only if you have durability data and construction application. Here's how to assess fit.
Nature Medicine and The Lancet are both top-tier journals, but they serve different audiences. Learn when to submit to each one.
Cell Reports and Scientific Reports are both open-access biology journals, but they're targeting completely different audiences and selectivity levels.
Both are open-access biology journals, but Cell Reports is selective while PLOS ONE is inclusive. Learn which one fits your work and career stage.
Both are prestigious journals, but JCI leans clinical while Nature Medicine emphasizes translational mechanism. Learn which one matches your paper.
Blood and Journal of Clinical Oncology are both elite, but Blood covers hematology broadly while JCO focuses on solid tumors and clinical oncology.
Both Wiley journals, both selective, but Advanced Materials demands novelty in synthesis or characterization. Advanced Functional Materials cares more about application. Here's how to choose.
Advanced Materials is 3× more selective and cites applied work. ACS Applied Materials is faster, broader, and accessible. Choose AM for materials breakthroughs, ACSA&I for applications that prove value.
Both are selective nanoscience journals under ACS. ACS Nano takes comprehensive studies, Nano Letters takes high-impact single results. Same acceptance rate, different article lengths.
Almost identical impact factors. Advanced Energy Materials is 4× more selective in practice because it demands energy application. Advanced Materials demands novelty in the material itself, not the application.
Both are elite nanotechnology journals. Small is more selective. Nano Letters reviews faster. Here's how to choose.
Journal of Hazardous Materials is a top-tier environmental and chemical safety journal with a 2024 impact factor of 11.3. We explain what the JIF number means and whether it should influence your submission decision.
Molecules is a broad-scope, open-access chemistry journal with a 2024 impact factor of 4.6. We break down what the Q2 ranking means and how it compares to selective chemistry venues.
Journal of Chemical Physics is a respected venue for physical chemistry and chemical physics research with a 2024 impact factor of 3.1. We explain the JIF ranking and scope.
International Journal of Hydrogen Energy is a leading venue for hydrogen, fuel cell, and renewable energy research with a 2024 impact factor of 8.3. Here's what the JIF means.
Frontiers in Immunology is a growing venue for immunology research with a 2024 impact factor of 5.9. We explain the Q1 ranking and what it means for authors.
International Journal of Biological has an impact factor of 8.5 (2024 JCR). It ranks 6/94 in its field. Here's what the IF means for your submission and whether International Journal of Biological is right for your work.
Journal of Materials Chemistry has an impact factor of 9.5 (2024 JCR). It ranks 63/460 in its field. Here's what the IF means for your submission and whether Journal of Materials Chemistry is right for your work.
RSC Advances has an impact factor of 4.6 (2024 JCR). It ranks 75/239 in its field. Here's what the IF means for your submission and whether RSC Advances is right for your work.
Sensors has an impact factor of 3.5 (2024 JCR). It ranks 24/79 in its field. Here's what the IF means for your submission and whether Sensors is right for your work.
Energy has an impact factor of 9.4 (2024 JCR). It ranks 3/79 in its field. Here's what the IF means for your submission and whether Energy is right for your work.
PLOS ONE and Scientific Reports both publish methodologically sound research without novelty filters. The choice comes down to cost, prestige, and your field's publishing culture.
Science and Scientific Reports are often conflated because both are multidisciplinary. But they're not alternatives. Science is selective and breakthrough-focused. Scientific Reports is inclusive and rigor-focused. Know which one actually fits your paper.
PNAS and Scientific Reports both publish across all sciences. But PNAS filters for significance and novelty. Scientific Reports filters for rigor. Choose based on whether your finding is genuinely novel.
JACS and Scientific Reports are both published broadly, but JACS is selective chemistry and Scientific Reports is inclusive multidisciplinary. For chemists, the choice is mechanistic novelty vs methodological soundness.
Angewandte Chemie and Scientific Reports both publish chemistry broadly. But Angewandte is selective general chemistry with novelty bar. Scientific Reports is inclusive and rigor-focused. Know which your chemistry fits.
NEJM is genuinely elite. IF 78.5, <5% acceptance, published since 1812. But it's not just selective—it's a specific venue for a specific kind of work. Here's the breakdown.
Cell is genuinely elite. IF 42.5, less than 5% acceptance, one of the top 3 most cited journals globally. But even strong labs get rejected. Here's the honest breakdown.
NAR is selective but accessible. IF 13.1, ~40% acceptance, published by Oxford University Press. A top choice for sequence analysis, bioinformatics, and structural biology work.
Sustainability is legitimate but controversial. IF 3.3, high acceptance (60%+), published by MDPI. Good for applied sustainability work, but carries MDPI reputation concerns.
JBC is established and respected in biochemistry. IF 3.9, moderate acceptance, published since 1905 by the American Society for Biochemistry and Molecular Biology.
Research Square combines preprint posting with optional paid peer review. But posting publicly before submission is not right for every researcher. Here are the main alternatives and what each one actually does.
Journal of the American Chemical Society impact factor is 15.6. Five-year JIF is 15.5. Quartile: Q1. Category rank: 17/239.
Angewandte Chemie International Edition has an impact factor of 16.9 in the 2024 JCR, the latest figure available in 2026. Here's where that ranks in chemistry, how it compares to JACS, and what the number actually signals about selectivity.
Physical Review Letters has an impact factor of 9.0 in the 2024 JCR — the latest figure available in 2026. Here's where that sits in physics journal rankings, how it benchmarks against Nature Physics and PRL alternatives, and what the IF signals about selectivity.
Chemical Engineering Journal has an impact factor of 13.2 in the 2024 JCR, ranked 3rd in chemical engineering. Here's what that means for authors, how it benchmarks against peers, and what the number tells you about the journal's scope and selectivity.
Science of The Total Environment has an impact factor of 8.0 in the 2024 JCR, placing it Q1 in environmental sciences. Here's what that ranking means, how it benchmarks against peers, and what the IF actually tells you about the journal's scope and selectivity.
Advanced Materials impact factor is 26.8. Five-year JIF is 28.9. Quartile: Q1. Category rank: 10/460.
International Journal of Molecular Sciences impact factor is 4.9. Five-year JIF is 5.7. Quartile: Q1. Category rank: 72/319.
Physical Review B impact factor is 3.7. Five-year JIF is 3.6. Quartile: Q2. Category rank: 66/187.
New England Journal of Medicine impact factor is 78.5. Five-year JIF is 84.9. Quartile: Q1. Category rank: 2/332.
ACS Applied Materials & Interfaces impact factor is 8.2. Five-year JIF is 8.5. Quartile: Q1. Category rank: 83/460.
Science accepts fewer than 7% of submissions, but that number hides a more useful fact: the 80% desk rejection rate means most papers never reach a reviewer. Understanding why changes how you should prepare your submission.
JACS doesn't publish an official acceptance rate, but the journal is selective about chemical significance, not just methodological quality. Understanding what editors look for changes how you frame your submission.
Angewandte Chemie International Edition doesn't publish its acceptance rate, but with a JIF of 16.9 and a reputation as one of the top two broad-scope chemistry journals, the bar is genuinely high. Here's what that means for your submission.
Physical Review Letters doesn't publish an official acceptance rate, but estimates put it around 25-30% of papers that survive initial screening. Here's what that means and how PRL's selectivity actually works.
Chemical Engineering Journal is one of the most-cited journals in its field with a JIF of 13.2, but it doesn't publish its acceptance rate. Here's what drives acceptance and how to prepare your submission.
Journal of Cleaner Production impact factor is 10.0. Five-year JIF is 10.7. Quartile: Q1. Category rank: 23/374.
Advanced Functional Materials impact factor is 19.0. Five-year JIF is 19.4. Quartile: Q1. Category rank: 9/187.
Astrophysical Journal impact factor is 5.4. Five-year JIF is 5.2. Quartile: Q1. Category rank: 17/84.
Cell impact factor is 42.5. Five-year JIF is 48.9. Quartile: Q1. Category rank: 3/319.
IEEE Access impact factor is 3.6. Five-year JIF is 3.9. Quartile: Q2. Category rank: 128/366.
Nucleic Acids Research impact factor is 13.1. Five-year JIF is 16.8. Quartile: Q1. Category rank: 13/319.
Sustainability has an impact factor of 3.3 in 2024, placing it Q2 in Environmental Sciences. Here's the honest picture of what that means, how it compares to competitors, and whether it's the right journal for your work.
The Journal of Biological Chemistry has an impact factor of 3.9 in 2024, a significant drop from its historical highs above 5. Here's what happened to JBC's IF, where it sits in the field, and who should still submit there.
Science of The Total Environment doesn't report an official acceptance rate, but desk rejection is significant for scope mismatches. Here's what editors actually look for and where most environmental science papers fail.
Advanced Materials is one of the most selective materials science journals, with an IF of 26.8 (JCR 2024) and aggressive desk rejection for work that doesn't reach its impact standard. Here's what actually gets in.
Nature desk-rejects more than 90% of submissions, usually within 4-6 weeks. For papers that reach peer review, total time to a first decision runs 4-6 months. Here's what the timeline looks like at every stage.
Science rejects more than 90% of submissions at the desk, often within 2-4 weeks. Papers that go to peer review take 3-5 months for a first decision. Here's the full timeline.
JACS handles about 40,000 submissions per year and provides first decisions in 4-8 weeks for most papers. Around 40-50% never reach external reviewers. Here's what the timeline looks like at every stage.
Nature receives more than 10,000 manuscripts per year and sends most back without review. This guide covers the submission requirements, what editors actually check, and how to give your paper the best chance of getting past the desk.
JACS handles 40,000+ submissions per year via ACS Paragon Plus. This guide covers manuscript types, characterization standards, cover letter expectations, and what Associate Editors look for before sending a paper out for review.
IJMS accepts around 30-40% of submissions, making it one of the more accessible Q1 journals in molecular sciences. Here's the full breakdown on selectivity, desk rejection, and what reviewers look for.
Physical Review B accepts around 60-65% of papers sent to review, but the desk rejection rate is notable. Here's what the selection process actually looks like for condensed matter and materials physics.
NEJM accepts about 5% of submitted papers, making it among the most selective journals in medicine. Here's the full breakdown on what clears the bar and what doesn't.
ACS Applied Materials & Interfaces accepts around 25-30% of submissions, making it selective but accessible for applied materials research. Here's what the review process looks like.
Sustainability accepts around 35-45% of submissions - accessible but not a rubber stamp. Here's what the review process looks like and what editors actually screen for.
Angewandte Chemie is one of the fastest top-tier chemistry journals. Communications get a first decision in 2-4 weeks, but full Articles take longer. Here's the complete timeline.
Physical Review Letters typically delivers a first decision in 4-8 weeks, but desk rejection rates are high. Here's what happens at each stage of the PRL review process.
Chemical Engineering Journal delivers first decisions in 4-8 weeks on average. High volume and an IF of 13.2 make it competitive. Here's the full review timeline.
Angewandte Chemie International Edition has specific formatting requirements that trip up first-time submitters. Here's everything you need to know before hitting submit.
Physical Review Letters has strict formatting rules and a high desk rejection rate. Here's everything you need to know about submitting to PRL.
Science of The Total Environment processes over 10,000 submissions per year. This guide covers manuscript types, formatting requirements, data sharing policies, and what handling editors check first.
Science is one of the three most prestigious journals in the world. Impact factor 45.8, acceptance rate under 7%, published by AAAS. But prestige alone isn't a reason to submit. Here's an honest breakdown.
JACS is the gold standard in chemistry. Impact factor 15.6, published by ACS since 1879, roughly 20% acceptance rate. Here's an honest assessment of who it's right for and who should look elsewhere.
Nucleic Acids Research doesn't publish its exact acceptance rate, but consistent author reports place it around 15-20%. Here's what selectivity looks like in practice, what triggers desk rejection, and what gets through.
JBC doesn't publish its official acceptance rate, but consistent author experience places it around 30-35%. Here's what that means in practice, what triggers desk rejection, and how the review process works.
Science of The Total Environment takes roughly 6-10 weeks to a first decision for papers that reach peer review. Desk rejections arrive faster, around 2-4 weeks. Here's what determines your timeline.
Advanced Materials takes 6-12 weeks to a first decision for papers that pass desk review. Desk rejection decisions arrive in 2-4 weeks. Here's a realistic timeline breakdown for one of materials science's top journals.
International Journal of Molecular Sciences (IJMS) is an MDPI journal known for fast review. First decisions typically arrive in 3-5 weeks. Here's what the timeline looks like and what influences your wait.
Physical Review B runs a thorough review process that takes 2-4 months for most papers. Here's what the timeline looks like, why it takes that long, and what the APS system's status labels mean.
NEJM has one of the fastest turnaround times in academic medicine: most papers get a first decision within 1-3 weeks. That speed reflects a very high desk rejection rate. Here's the complete timeline.
Chemical Engineering Journal (JIF 13.2, Q1) is one of the top journals in chemical engineering and applied chemistry. This submission guide covers what you need to know before you submit: formatting, scope, common desk rejection triggers, and what reviewers look for.
Advanced Materials (JIF 26.8, Q1) is one of the most selective materials science journals. This submission guide covers format requirements, what passes the desk, what reviewers actually assess, and how to improve your odds.
International Journal of Molecular Sciences (MDPI) accepts a relatively high proportion of submitted papers, but there are still formatting requirements, scope constraints, and common mistakes that trip up first-time submitters. This guide covers everything you need.
ACS Applied Materials & Interfaces typically delivers a first decision in 5-8 weeks from submission. Here's how the editorial process works and what you can do to keep things moving.
Journal of Cleaner Production processes most submissions within 6-10 weeks to first decision. Here's how the review process works and what factors affect your timeline.
Advanced Functional Materials typically delivers a first decision in 4-8 weeks. The journal is highly selective, and desk rejection is fast. Here's what to expect at every stage.
The Astrophysical Journal runs a fast, transparent review process. Most papers get a first decision in 4-8 weeks. Here's what to expect from submission to publication.
IEEE Access is one of the fastest major engineering journals. Most first decisions arrive in 3-6 weeks. Here's how the process works and what to do if things slow down.
Nucleic Acids Research is fairly predictable by molecular biology standards. Expect about 45 days to a first decision if your paper reaches review, with faster outcomes for desk rejections.
Sustainability is quicker than many environmental journals, but the speed depends a lot on reviewer response and how clean the submission is on day one.
JBC is not the fastest biochemistry journal, but it is fairly predictable. Most papers that reach review hear back in roughly 8 to 12 weeks.
PRB is a workhorse journal for condensed matter physics. It is selective, but not theatrical. If the physics is solid and the story is framed clearly, it can be a very sensible target.
NEJM is brutally selective, but not mysterious. Editors want large, practice-changing clinical evidence, clean reporting, and no confusion about why the paper matters.
Journal of Cleaner Production accepts roughly 25-30% of submissions, making it moderately selective within its field. Here's the breakdown of what that rate means and what reviewers look for.
Advanced Functional Materials accepts about 18-22% of submissions, making it genuinely selective and competitive. Here's the breakdown of what that rate means and what determines acceptance.
Astrophysical Journal accepts roughly 35-40% of submissions, making it moderately selective for a top-tier astronomy venue. This breakdown explains what that rate means and what reviewers prioritize.
IEEE Access accepts approximately 45-50% of submissions, making it one of the most open IEEE journals. This guide explains what that high acceptance rate means and what reviewers still look for.
Here's everything you need to know about submitting to Science: manuscript types, formatting rules, what the cover letter should include, and what the editors actually check before peer review.
Cell Reports publishes high-quality cell biology with solid selectivity. Here's what editors actually look for at desk review and in peer evaluation.
Molecular Systems Biology is selective and wants integrated frameworks plus experimental validation. Single-gene studies or purely computational papers rarely succeed here.
This open-access journal publishes ~1,000 papers/year in hematology and oncology. Moderate selectivity, fast decisions, strong field reach. Good for mechanistic oncology studies.
PROGRESS IN MATERIALS SCIENCE is one of materials science's highest-impact journals, IF 31.4. But it's invitation-only for reviews, not a submission venue.
Nature Reviews Nephrology is a prestigious invited-review journal. You don't submit primary research here. If invited to write a review, it's a career milestone.
ACS Applied Materials & Interfaces submission guide with manuscript limits, formatting rules, cover letter tips. What editors want and how to avoid desk rejection.
Journal of Cleaner Production submission guide with manuscript limits, formatting rules, cover letter tips. What editors want and how to avoid desk rejection.
Advanced Functional Materials submission guide with manuscript limits, formatting rules, cover letter tips. What editors want and how to avoid desk rejection.
Astrophysical Journal submission guide with manuscript limits, formatting rules, cover letter tips. What editors want and how to avoid desk rejection.
IEEE Access submission guide with manuscript limits, formatting rules, cover letter tips. What editors want and how to avoid desk rejection.
Submitting to Cell? Learn how editors screen breadth, mechanism, evidence depth, and why many strong papers still die before review.
Submitting to JAMA? Learn how editors judge breadth, endpoint strength, methods, and whether a study truly belongs in general medicine.
Submitting to JCI? Learn how editors judge human relevance, mechanistic depth, disease fit, and whether a paper feels truly translational.
Submitting to NEJM? Learn how editors judge practice impact, endpoint strength, study authority, and whether a paper really belongs in broad medicine.
Submitting to Nature? Learn how editors judge breadth, conceptual force, claim discipline, and whether a paper really deserves top-tier review.
Submitting to Nucleic Acids Research means more than cleaning up your manuscript. The journal wants utility, validation, and open science discipline, especially for tools, databases, and computational resources.
Sustainability is broad, but not directionless. Papers do better when they connect a real-world sustainability problem to a usable solution, policy path, or systems-level insight.
JBC is not impressed by vague molecular storytelling. The journal wants hard mechanistic evidence, complete methods, and a clean link between biochemistry and biological significance.
Yes, Angewandte Chemie International Edition is a very good journal, but it's not the right target for every strong chemistry paper. Mechanistic depth and broad chemistry interest matter a lot.
Yes, Physical Review Letters is a very good journal, but only when the result really feels like a physics letter: concise, significant, and broad enough to matter beyond one narrow slice of the field.
ACS Nano has an impact factor of 16.0 in 2024, making it a top-tier journal in materials science and nanotechnology. Here's what the metrics mean and whether your work belongs there.
Analytical Chemistry impact factor is 6.7. Five-year JIF is 6.6. Quartile: Q1. Category rank: 10/111.
Applied Catalysis B has an impact factor of 21.1 in 2024, making it the #1-ranked journal in its field. Here's what to know before submitting.
Applied Energy impact factor is 11.0. Five-year JIF is 11.2. Quartile: Q1. Category rank: 12/175.
Applied Physics Letters has an impact factor of 3.6 in 2024. Here's what that means, how it compares to similar journals, and what to expect if you submit.
Chemical Engineering Journal is genuinely selective and prestigious. IF 13.2, ranked #3 out of 83 chemical engineering journals. It's not a journal of last resort. Here's what you need to know.
Science of The Total Environment is a real, selective journal with genuine influence in environmental science. IF 8.0, Q1 ranking. Here's an honest assessment of fit.
Advanced Materials is elite. IF 26.8. Ranked top 10 globally in materials science. Ruthlessly selective. Here's what you're up against.
International Journal of Molecular Sciences is a legitimate, indexed journal with moderate prestige. IF 4.9, Q1. Open-access, reasonable acceptance rate. Here's whether it's right for your paper.
Physical Review B is a cornerstone journal for condensed matter physics. IF 3.7, strong within the field, no publication charges. Here's the real assessment.
Submitting to PNAS? Learn how editors judge scientific significance, breadth, completeness, and whether your significance statement actually works.
JACS desk rejects papers when the chemistry feels incremental, the mechanism is thin, the scope is narrow, or the manuscript does not show why working chemists should care.
Angewandte desk rejects chemistry that looks incremental, underexplained, weakly benchmarked, or not useful enough to matter to a broad chemistry readership.
PRL desk rejects papers that may be solid physics but do not yet look like a genuinely significant Letter for a broad physics audience.
Chemical Engineering Journal desk rejects papers that may have sound experiments but do not yet make a convincing engineering case in terms of application, benchmarking, and scale-relevant thinking.
Submitting to Nature Communications? Learn how editors judge novelty, completeness, breadth, and whether a paper really deserves review.
Submitting to PLOS ONE? Learn how editors screen methodological validity, reporting, ethics, and whether a paper is reviewable as sound science.
Submitting to Science? Learn how editors judge breadth, consequence, completeness, and whether a paper deserves review in a top general journal.
The Lancet is among the world's highest-impact medical journals, but it desk rejects papers with narrow scope, weak evidence strength, or insufficient global or population-level consequence.
At STOTEN, the fast rejection usually isn't about grammar or formatting. It's about whether your paper teaches anything beyond a local monitoring exercise.
At Advanced Materials, good data isn't the standard. That's the entry fee. The real question is whether the paper feels field-shifting enough to deserve reviewer time.
IJMS is broad, but not careless. The fast rejection usually hits papers that say 'molecular' in the title while offering only thin mechanism, weak validation, or routine assay packages.
PRB isn't a home for any competent condensed matter paper. Editors reject quickly when the manuscript is really materials characterization, routine DFT, or device work with a thin physics wrapper.
At NEJM, a strong paper still gets rejected if it isn't broad, decisive, and practice-changing. Prestige doesn't reward effort. It rewards consequence.
ACS Applied Materials & Interfaces accepts solid materials science and surface chemistry work, but it desk rejects papers that are incremental, narrow in application, or lacking clear device or industrial relevance.
Journal of Cleaner Production accepts sustainability, waste, pollution prevention, and industrial ecology work, but desk rejects papers that are narrow, lack systemic perspective, or fail to show real environmental or economic benefit.
Advanced Functional Materials accepts high-impact material innovation with clear functional advantage, but desk rejects incremental property improvements or papers lacking real device demonstration.
Astrophysical Journal accepts high-quality observational and theoretical astrophysics, but desk rejects papers with statistical problems, weak evidence for extraordinary claims, or insufficient novelty.
Science Translational Medicine impact factor is 14.6. Five-year JIF is 16.0. Quartile: Q1.
Nature Medicine impact factor is 50.0. Five-year JIF is 52.4. Quartile: Q1. Category rank: 1/195.
Circulation impact factor is 38.6. Five-year JIF is 35.9. Quartile: Q1. Category rank: 1/98.
Nature Biotechnology impact factor is 41.7. Five-year JIF is 59.5. Quartile: Q1. Category rank: 2/177.
BMJ impact factor is 93.6. Quartile: Q1. Category rank: 3/325.
JAMA impact factor is 55.0. Five-year JIF is 64.7. Quartile: Q1. Category rank: 4/332.
eLife is not listed with a JIF in JCR 2024. Here is the practical context for authors evaluating the journal.
PNAS impact factor is 9.1. Five-year JIF is 10.6. Quartile: Q1. Category rank: 14/135.
Cell Reports impact factor is 6.9. Five-year JIF is 8.1. Quartile: Q1. Category rank: 44/204.
AJE is one of the most trusted language editing services in academic publishing. Manusights is a peer review simulation service. They overlap in the pre-submission space but solve different problems entirely.
Editage and Manusights both sit in the manuscript preparation space, but they solve very different problems. One cleans up your writing. The other tells you whether a reviewer would reject your paper.
Science Advances desk-rejects about 75% of submissions. Your cover letter is the first thing editors read. Here's how to write one that actually works.
PLOS ONE isn't predatory. It's a legitimate, peer-reviewed, PubMed-indexed journal. But its high acceptance rate and open-access model cause confusion. Here's the full picture.
JCI Insight is JCI's sister journal with an IF of 6.1. It publishes strong translational work that doesn't meet JCI's bar. Here's the full picture for submission decisions.
PNAS Nexus got its first official IF of 3.5 in 2024 JCR. It's the open-access companion to PNAS. Here's what the early data tells us about where this journal is heading.
Both are Nature Portfolio journals, but they serve different purposes. Communications Biology is selective; Scientific Reports isn't. Here's how to decide.
Nature and Nature Communications are both top journals, but they aren't interchangeable. Here's a practical guide to deciding where your paper actually belongs.
Scientific Reports sits at IF 3.9 in the latest JCR release. That's not elite tier, but it's still a high-volume, indexed venue with broad visibility.
Scientific Reports is more permissive than selective flagship journals, but acceptance still depends on methods, reporting quality, and reviewer confidence.
Nature Communications is selective even though it's high volume. Most rejections happen early at editorial screening.
Science Advances can be fast at desk decision and strict at external review. Here's a practical map so you don't lose weeks on avoidable errors.
Both journals are strong. The better choice depends less on brand and more on your manuscript's shape, audience, and evidence depth.
These journals aren't substitutes. PNAS and Nature Communications reward different manuscript profiles and career goals.
European Heart Journal sits at the top of cardiology publishing. Here's an honest look at its standing and who it's right for.
If your Science Advances status has not moved in weeks, this guide breaks down what each stage means and where delays usually happen.
Both talk about AI-assisted review, but they are built for different jobs. Here is the practical decision split.
ScholarsReview is feature-rich for AI writing workflows. Manusights is narrower and more submission-focused. Here is where each fits.
PaperReview.ai is very fast for AI triage. Manusights is built for deeper submission calls. Here is a clean way to choose.
If you are choosing between two AI-first review tools, the key difference is not branding. It is the type of feedback each one is built to surface.
The market is crowded and most pages blur the differences. This one focuses on verifiable product scope, not hype.
Science is still one of the hardest journals to place in. The impact factor confirms status, but it doesn't replace fit analysis.
If you're searching NEJM Evidence impact factor, the key point is JIF status and how committees in your field view this title.
JCO remains a top destination for clinical oncology studies. The number is strong, but fit and trial quality still decide outcomes.
NSMB has a focused audience and strict standards. JIF helps, but your structural and mechanistic depth matters much more.
NAR stays a strong venue in molecular biology and genomics. The right paper type matters more than chasing an average citation metric.
BMJ accepts about 7% of submissions with IF 42.7 and accepts about 7% of submissions. It's also fully open access. Here's what you need to know.
The Lancet desk rejects over 90% of submissions. If you're Under Review, you're already in a select group. Here's what happens next.
If your Science Advances submission shows Under Evaluation, it has passed initial checks and is being assessed by the editorial team or reviewers. Here's what that status means and what to expect next.
The Journal of Clinical Investigation (JCI) has been publishing translational research since 1924. With an IF of 13.3 and acceptance rate around 10%, it's one of the most respected venues for mechanistic clinical science. Here's who should submit.
Nature has an impact factor of 48.5 and is the most cited scientific journal in the world. It desk-rejects most submissions in under a week. Here's who genuinely belongs there and when a Nature family journal is the right call.
The NC cover letter is what editors read before they read your paper. Get it wrong and the deck is stacked against you before they open the file. Here's what it actually needs to say.
The BMJ has an impact factor of 42.7 and publishes some of the most influential clinical research in the world. It's also highly selective and has a distinct editorial focus that most submissions miss.
NEJM is the most cited medical journal in the world. It's also one of the hardest to get into, with over 80% of manuscripts desk-rejected before peer review. Here's who belongs there and what it actually takes.
Nature Medicine has the highest impact factor of any clinical journal. That means it's extraordinarily selective. Here's an honest look at who should submit, what editors are screening for, and why most papers that belong there don't make it past the desk.
The Lancet is one of the four most prestigious medical journals. At IF 88.5 with around 6% acceptance, it's also extremely selective and has a distinct global health focus that sets it apart from NEJM and JAMA.
NEJM desk-rejects more than 80% of submissions, often within 7 days. The cover letter is your first and sometimes only chance to make the case for why your paper belongs there.
JAMA receives over 6,000 manuscripts per year and publishes fewer than 5% of them. Here's what distinguishes it from NEJM and The Lancet, and who should actually be targeting it.
Nature Biotechnology has an impact factor of 33.1 and accepts roughly 8% of submissions. It's the top journal for biotech platforms, cell and gene therapies, and translational tools. Here's who belongs there.
Nature Genetics has an impact factor of 27.5 and is one of the most selective genetics journals. It publishes disease gene discovery, GWAS findings, population genetics, and functional genomics. Here's who belongs there.
Circulation has an impact factor of 38.6 and accepts around 8% of submissions. It's the flagship journal of the American Heart Association and one of the top cardiovascular journals in the world. Here's who belongs there.
JAMA receives 6,000+ manuscripts per year and publishes fewer than 5%. The cover letter is your argument for why your research belongs in the most-read general medical journal in the US.
Scientific Reports and PLOS ONE are both megajournals with technical-soundness-only peer review. The differences come down to field community, publisher brand, and APC structure. Here's how to choose.
Nature Communications and PNAS both publish multidisciplinary high-impact research. The IF gap is real but doesn't tell the whole story. APC differences, field communities, and the Significance Statement requirement all factor into the right choice.
Most researchers know peer review exists but haven't seen it from the reviewer's side. Here's the full process from submission to published decision - including where most papers die, what reviewers actually check, and how long each stage takes.
eLife and PLOS ONE both challenged traditional peer review but built very different journals. eLife is a selective, high-quality biology journal. PLOS ONE is a megajournal for technically sound work. Here's why they're not interchangeable.
Nature Medicine desk-rejects approximately 85% of submissions before external review. This guide covers what the editorial team is actually looking for, the cover letter mistakes that trigger rejection, and how long the full process takes.
JCI's IF is 13.6 with a 60-70% desk rejection rate. The journal wants mechanistic studies with direct human disease relevance - and is very specific about what that means. Here's how to submit, what to expect from review, and when JCI Insight is the better target.
NEJM and The Lancet are the two most-cited clinical journals in the world. The IF gap is real but the more important difference is editorial philosophy: NEJM skews US clinical practice; The Lancet skews global. Here's how to choose.
Nature Biotechnology accepts under 5% of submissions. Here's what the editors are actually screening for and how to give your paper its best shot.
The Lancet rejects over 95% of submissions. Here's what the editors screen for at the desk stage and how to structure a submission that has a real shot.
Impact factor is a simple formula that gets complicated fast. Here's exactly what it measures, what it doesn't, and how researchers actually use it.
Most researchers don't know there are three reliable free ways to look up any journal's impact factor. Here's the fastest method and what to do when IF isn't listed.
Publishing your first paper is one of the most disorienting parts of an academic career. Here's the full process, from choosing a journal to responding to reviewers.
NEJM rejects over 90% of submissions at the desk. Here's what editors are screening for and how to give your manuscript its best shot at the world's highest-IF medical journal.
The discussion section is where most papers lose editors and reviewers. Here's the structure that works and the 4 mistakes that kill otherwise strong manuscripts.
NEJM accepts 5-6% of manuscripts and desk-rejects over 90%. The numbers don't tell the whole story , here's what actually determines whether your paper clears each stage.
JAMA's overall acceptance rate is around 5%, with over 80% desk-rejected before peer review. Here's what the numbers mean and what actually determines whether your paper clears each stage.
JAMA rejects ~80% of submissions at the desk. Here's the complete submission guide , what editors screen for, how to format your manuscript, and when a JAMA Network journal is the better target.
The Lancet accepts roughly 4-5% of submitted manuscripts, with over 80% desk-rejected in 1-2 weeks. Here's what the stage-by-stage data looks like and what determines whether your paper clears each stage.
Scientific Reports has a 3.9 impact factor, 57% acceptance rate, and carries the Springer Nature name. Some researchers swear by it. Others question the model. Here's the honest answer on all of it.
Nature Communications IF is 15.7 in 2024: the highest of any fully open-access multidisciplinary journal. But the IF alone doesn't tell you whether to submit. Here's the full picture: what it means, how it compares, and when Nature Communications is the right call.
Science Advances hit an impact factor of 12.5 in 2024, recovering from a dip to 11.7 in 2023. Here's the full trend, where it ranks vs similar journals, and what that number actually means for your chances of getting published.
PNAS and Science Advances are both broad-scope journals below Nature/Science but above most specialty journals. Here's how they compare.
Scientific Reports is a real, indexed journal, but it's not selective, and its IF has been declining for years. Here's an honest take on whether your work belongs there.
Nature Communications is fast by high-impact journal standards. Desk decisions in under 2 weeks, first decisions in about a month. Here's exactly what happens at each stage.
Science Advances accepts about 25% of submissions. Here's the full breakdown: desk rejection rate, how long each stage takes, and what the editors are actually looking for.
Cell rejects over 85% of submissions at the desk before they reach peer review. Here's what the editorial process looks like, what the journal's structural requirements are, and how to write a paper that survives initial screening.
Nature Genetics desk-rejects over 85% of submissions. Here's what the editorial process looks like, what the journal prioritizes in initial screening, and how to position your paper before you submit.
Circulation is the flagship journal of the American Heart Association and one of the fastest major journals for desk decisions. Here's what the submission process looks like, what the editorial team prioritizes, and how to avoid the most common rejection reasons.
Nature Medicine has the highest impact factor of any clinical research journal. At ~7% acceptance, here's what the numbers tell you about who gets in.
PNAS has an impact factor of 9.1 and a complicated reputation. For decades, NAS members could essentially self-publish there through the Contributed track. That changed in 2022. Here's an honest look at what PNAS is now, who it's for, and whether it belongs on your target list.
eLife fundamentally changed how it operates in 2023. It no longer makes traditional accept/reject decisions - it publishes all papers that complete peer review. The change is controversial. Here's what it means for your career and whether eLife still makes sense as a target.
Science Advances carries the AAAS brand - the same organization that publishes Science. Its 2024 impact factor is 12.5 and it's more selective than it looks. But is it worth $5,000 and who actually does well there?
PLOS ONE publishes over 20,000 papers a year, uses soundness-only peer review, and has an impact factor of 2.6. People call it predatory. They're wrong. Here's what PLOS ONE actually is and when it's the right journal for your work.
Cell Reports has an impact factor of 6.9 and publishes in a format designed for complete, data-rich stories. It's a legitimate journal from Cell Press. But is it worth the $5,790 APC, and does it move careers? Here's a direct assessment.
Nature Communications has an impact factor of 15.7 and publishes around 9,000 papers a year. That combination raises a fair question: is it genuinely selective, or is it just a high-volume journal with a prestigious name attached? Here's an honest answer.
Most researchers don't know exactly what a pre-submission peer review covers until they've received one. Here are the six components that a serious review includes, what a 10-page review looks like versus a shallow one, and how to actually use the feedback.
Finding a pre-submission reviewer sounds simple until you try. Your closest colleagues have conflicts. Your lab mates are too polite. And not everyone who reads manuscripts can give you the feedback that actually prevents desk rejection.
PLOS ONE's acceptance rate has dropped from 68% in 2015 to 31% today. That's not a sign the journal got harder to publish in. It's a sign of who's submitting now, and understanding that changes how you should read the number.
Cell Reports' 15-20% acceptance rate sounds daunting. But that number includes papers that never had a shot at this journal. Once you understand how the rate breaks down, submitting to Cell Reports looks very different.
Nature Communications handles 50,000+ submissions per year and desk-rejects more than half of them within 9 days. Here's what happens at every stage, from the documents you need before you submit to what you do after acceptance.
Cancer Cell accepts 8-10% of submissions and desk rejects in 5 days. Here's the full review timeline, what editors actually want, and why most papers don't make it past screening.
Cell Reports has an unusually fast initial screening: 5 days median to a first editorial decision. But that speed comes with strict expectations. Here's what the process looks like.
Scientific Reports has one of the longest review timelines in open-access publishing: around 120 days on average. Here's what happens at each stage and why it takes so long.
Lancet Oncology's IF of 35.9 places it second in clinical oncology behind JCO. The key difference: Lancet Oncology requires global applicability, not just strong trial results from a single country.
JCO's impact factor of 41.2 makes it the highest-IF journal in clinical oncology. The editorial test is specific: does your study answer a question oncologists face in clinic every day? If not, JCO probably isn't the right venue.
The Lancet's impact factor of 88.5 makes it the highest-IF medical journal after NEJM. But the editorial bar is specific: Lancet explicitly prioritizes research with global health implications, not just strong clinical trial results.
Nature's impact factor dropped from 69.5 in 2022 to 48.5 in 2024 after COVID-related citations normalized. Here's the full trend, what it means for your submission, and the one test every Nature paper must pass.
Both are high-impact open-access multidisciplinary journals. Nature Communications has the higher IF. Science Advances is more selective. Here's how to choose.
Counterintuitive but true: JCI can be the better strategic target than higher IF journals when your paper has real mechanistic depth plus human relevance but not headline trial scale.
Most teams submitting to NEJM are not asking if the science is good. They are asking if the clinical consequence is large enough to justify the editorial risk. That is the real filter.
A Pangram Labs study found 21% of ICLR reviews were fully AI-generated: not AI-assisted, fully written by an LLM. In 2026, the structural incentives driving this are stronger, not weaker. Here's the problem and what researchers can do about it.
PLOS ONE's impact factor is 2.6 in 2024: and PLOS ONE itself tells you not to use it. Here's why the number is uniquely misleading for this journal, what actually matters when deciding whether to submit, and how it compares to similar open-access outlets.
eLife made headlines in 2023 by abandoning the impact factor entirely. For researchers deciding where to submit, that raises real questions about prestige, discoverability, and whether the journal is still worth the $2,000 APC. Here's the honest answer.
Scientific Reports has a 57% acceptance rate, which sounds like a sure thing. About 30% of submissions never reach peer review. Here's what the editorial check actually evaluates and when Scientific Reports is the right choice.
Cell Reports is the open-access workhorse of Cell Press. At IF 6.9 with 15-20% acceptance rate, it takes rigorous work that didn't make higher Cell Press journals. Here's what reviewers actually want.
PNAS has two submission tracks most researchers dont fully understand: Direct Submission and Contributed. Knowing which to use and how each is evaluated is the first step.
Nature Communications gets 50,000+ submissions per year and accepts about 20% of them. The review process moves faster than most journals at this impact factor, but initial screening is strict.
PLOS ONE has a 31% acceptance rate, but that doesn't mean anything goes. Reviewers check scientific soundness and methodology rigorously. Here's what the submission process actually looks like.
Nature desk rejects 70% of submissions. Cell rejects 65%. Here's how to avoid desk rejection and get your paper to peer review.
You've hit submit. Now what? Here's everything that happens to your paper from that moment until you get a decision.
Sometimes reviewers are wrong. Here's how to disagree professionally while protecting your paper's chances of acceptance.
Major revision doesn't mean your paper is in trouble. Minor revision doesn't mean you're home free. Here's what each decision actually signals.
After reading 50 cover letters for journal submissions in a single week, the patterns were painfully obvious. Here's what stood out.
Pre-submission review costs $800-2,000. For early-career researchers targeting competitive journals, it often pays for itself. Here's when it does: and when it doesn't.
Reviewers don't need a statistics PhD to spot these errors. Here are the 10 statistical mistakes that get papers rejected, and how to fix each one before you submit.
21% of ICLR 2025 reviews were fully AI-generated. Not AI-assisted: fully written by an LLM. Here's what that means for your next submission and how to protect your work.
The journal you pick matters more than most researchers think. A great paper sent to the wrong journal gets rejected. Here's how to match your manuscript to the right target.
Reviewers decide how they feel about your paper in the first 90 seconds. Most of that time is spent on the abstract. Here's how to make those seconds count.
You've finished the draft. You're ready to submit. But are you? Here are the warning signs that your paper needs more work.
Got reviewer comments back? Here's how to write a response letter that gets your paper accepted, from scientists who review for top journals.
Most desk rejections aren't about bad science - they're about fixable problems editors spot in the first 60 seconds. Here's what they look for.
With 18.5% success rate, 81.5% of early-career researchers don't get funded on first try. Here's how to protect your publication record and maximize your odds.
Headlines said budget cuts. Final numbers show budget went up. Both are true. Here's the full story of what happened with NIH funding in 2025.
Desk rejection hurts, but it's not the end of your paper. About 40% of manuscripts get desk rejected at high-impact journals. Here's what to do in the next 2-4 weeks to turn this around....
Scientific Reports is one of the easiest high-volume journals to publish in, with a 36% acceptance rate and straightforward submission process. If you're preparing your first submission, here's what h...
Nature Communications article processing charges are €5,390 (roughly €5,390 USD) as of 2026. That's for full open access. Here's what that buys you, who qualifies for waivers, and whether it's worth p...
PLOS ONE's median time to first decision is 35-45 days, but that number hides a lot of variation. Some papers get decisions in 18 days. Others wait 90+. Here's what determines your timeline and what y...
The Science Advances submission process is faster than most high-impact journals, but that speed comes with stricter initial screening. If you're preparing to submit, here's what happens at each stage...
Getting past the NEJM desk is the hardest part. If your paper shows Under Review, you're in a small minority. Here's what happens next.
Cell's ~8% acceptance rate masks a two-stage filter. Most papers never reach a reviewer. Here's the real breakdown.
Frontiers in Immunology is one of the most published-in immunology journals, but its high acceptance rate raises questions about selectivity.
Nature and Cell are both top-tier for biology, but they want different things. Here's how to choose between them.
Cell is one of the hardest journals to publish in. If your paper shows Under Review, here's what's actually happening and how long each stage takes.
Most cover letters fail because researchers write summaries instead of pitches. Here are 5 complete, filled-in templates for different journal tiers and fields: copy, adapt, submit.
PNAS's acceptance rate dropped after the 2022 reforms eliminated the Contributed track. At 15%, it's more competitive than ever. Here's what that means.
PNAS has clearer status labels than most journals, but 'Under Review' can still feel like a black box. Here's what's actually happening at each stage.
Gut is one of the top gastroenterology journals, but it's also fiercely competitive. Here's an honest look at whether your GI paper belongs there.
JAMA and NEJM are both top-tier clinical journals, but they have different editorial personalities. Here's how to decide between them.
Nature's acceptance rate is under 8%, but that number is misleading. Most rejections happen at the desk, and the papers that make it to review have much better odds.
The Krebs cycle paper got rejected because the journal had too many letters in the queue. The Higgs boson paper was never reviewed. Here's what happened after: and what it means for yours.
You just got desk rejected. Here's what that means, why it happened, and the step-by-step plan for what to do next.
If your Nature Communications submission shows Under Consideration, your paper is somewhere between desk review and peer review. Here's what that actually means and when to expect a decision.